Rituximab retreatment at clinical relapse cost-effective in RA

(HealthDay)—Rituximab retreatment at clinical relapse is at least as cost-effective as a more intensive regimen in longstanding rheumatoid arthritis (RA), according to a study published in the July is

Updated on: April 08,2024

Rituximab retreatment at clinical relapse cost-effective in RA

(HealthDay)—Rituximab retreatment at clinical relapse is at least as cost-effective as a more intensive regimen in longstanding rheumatoid arthritis (RA), according to a study published in the July is

Updated on:April 08,2024

How a virus that infects 50% of people is helping develop new cancer treatments

by Rebecca Aicheler,The ConversationCredit: AI-generated imageMost of us have heard of viruses such asmeaslesandmumps—not to mention the more seriousHIVandEbo

Updated on: May 07,2024

How a virus that infects 50% of people is helping develop new cancer treatments

by Rebecca Aicheler,The ConversationCredit: AI-generated imageMost of us have heard of viruses such asmeaslesandmumps—not to mention the more seriousHIVandEbo

Updated on:May 07,2024

Possible new biomarker for better detection of numerous inflammatory diseases

by Kiel UniversityTryptophan concentrations in the blood were significantly reduced in 9 of 13 chronic inflammatory diseases examined. Credit: S. Klahn, Exzellenzcluster PMITryptophan is an essen

Updated on: March 30,2024

Possible new biomarker for better detection of numerous inflammatory diseases

by Kiel UniversityTryptophan concentrations in the blood were significantly reduced in 9 of 13 chronic inflammatory diseases examined. Credit: S. Klahn, Exzellenzcluster PMITryptophan is an essen

Updated on:March 30,2024

Boosting CAR-T cell therapies from under the skin

by Benjamin Boettner,Harvard UniversityT-cell enhancing scaffolds can be locally injected under the skin following CAR-T cell therapy, and allowcirculating CAR-T cells to infiltrate their 3-dime

Updated on: June 15,2024

Boosting CAR-T cell therapies from under the skin

by Benjamin Boettner,Harvard UniversityT-cell enhancing scaffolds can be locally injected under the skin following CAR-T cell therapy, and allowcirculating CAR-T cells to infiltrate their 3-dime

Updated on:June 15,2024

Lymph node-like biomaterial scaffold for augmenting CAR-T cell therapy

byScience China PressOn the top, the schematic illustration shows the structure of scaffold, the seeding and proliferation of CAR-T cells within the scaffold after intratumor injection. On the b

Updated on: March 27,2024

Lymph node-like biomaterial scaffold for augmenting CAR-T cell therapy

byScience China PressOn the top, the schematic illustration shows the structure of scaffold, the seeding and proliferation of CAR-T cells within the scaffold after intratumor injection. On the b

Updated on:March 27,2024

Targeting ion channels to manage osteoarthritis pain

by Melissa Rohman,Northwestern UniversityThe image depicts two drug receptor sites with the molecular structure of the Nav1.7 channel, and tamoxifen’s attenuation of nociceptor action potentials

Updated on: May 14,2024

Targeting ion channels to manage osteoarthritis pain

by Melissa Rohman,Northwestern UniversityThe image depicts two drug receptor sites with the molecular structure of the Nav1.7 channel, and tamoxifen’s attenuation of nociceptor action potentials

Updated on:May 14,2024

Study offers insight into management of patients who have interstitial pneumonia with autoimmune features

by UT Southwestern Medical CenterCredit: Unsplash/CC0 Public DomainInterstitial pneumonia with autoimmune features (IPAF) is a disease with many possible causes and no standard of care, making it

Updated on: June 01,2024

Study offers insight into management of patients who have interstitial pneumonia with autoimmune features

by UT Southwestern Medical CenterCredit: Unsplash/CC0 Public DomainInterstitial pneumonia with autoimmune features (IPAF) is a disease with many possible causes and no standard of care, making it

Updated on:June 01,2024

A new pathway to 'reprogram' killer cells

by University of BernNK cells (brown) patrolling between cells of a healthy human lymph node. Credit: Institute of Pathology, University of BernThe so-called natural killer (NK) cells are cells o

Updated on: May 08,2024

A new pathway to 'reprogram' killer cells

by University of BernNK cells (brown) patrolling between cells of a healthy human lymph node. Credit: Institute of Pathology, University of BernThe so-called natural killer (NK) cells are cells o

Updated on:May 08,2024

Study shows genetically modified pluripotent stem cells may evade immunological rejection after transplantation

by University of ArizonaGeneration of an HLA-I/II and MICA/B-deficient hESC line (A) Representation of the Cas9 editing strategy. Wild-type H1 hESCs were transfected with a Cas9 construct and up

Updated on: March 07,2024

Study shows genetically modified pluripotent stem cells may evade immunological rejection after transplantation

by University of ArizonaGeneration of an HLA-I/II and MICA/B-deficient hESC line (A) Representation of the Cas9 editing strategy. Wild-type H1 hESCs were transfected with a Cas9 construct and up

Updated on:March 07,2024

Novel mechanism of ILC2 immune cell development may be involved in exacerbating allergic diseases

byChiba UniversityResearchers identify a G3SE-dependent mechanism of ILC2 development. Credit: Yosuke Toda and Arifumi Iwata from Chiba UniversityOverproduction of Group 2 innate lymphoid cells

Updated on: July 11,2024

Novel mechanism of ILC2 immune cell development may be involved in exacerbating allergic diseases

byChiba UniversityResearchers identify a G3SE-dependent mechanism of ILC2 development. Credit: Yosuke Toda and Arifumi Iwata from Chiba UniversityOverproduction of Group 2 innate lymphoid cells

Updated on:July 11,2024

Biomarkers may ID rheumatoid arthritis patients with and without active disease

Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) values may differentiate between rheumatoid arthritis (RA) patients with and without active disease, according to a systemat

Updated on: May 29,2024

Biomarkers may ID rheumatoid arthritis patients with and without active disease

Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) values may differentiate between rheumatoid arthritis (RA) patients with and without active disease, according to a systemat

Updated on:May 29,2024

Study compares hospitalized infection risk for biologics in RA

(HealthDay)—For patients with rheumatoid arthritis (RA) with prior biologic exposure, the risk of hospitalized infection is increased with etanercept, infliximab, and rituximab versus abatacept, accor

Updated on: April 08,2024

Study compares hospitalized infection risk for biologics in RA

(HealthDay)—For patients with rheumatoid arthritis (RA) with prior biologic exposure, the risk of hospitalized infection is increased with etanercept, infliximab, and rituximab versus abatacept, accor

Updated on:April 08,2024